Giovanni Migliaccio, Scientific Director of CVBF and member of the Board of Directors of the European Paediatric Translational Research Infrastructure (EPTRI), will be speaking at the upcoming international congress on Rare Diseases and Orphan Drugs organized by Rare Diseases Greece (RDG), member of EURORDIS-Rare Diseases Europe. The Congress, taking place in Athens on February 29th and March 1st, brings together key stakeholders across the rare disease community to promote collaboration and advance rare disease strategies.

Under the theme “Navigating the Uncharted,” the Congress will explore policy developments, regulatory frameworks, unmet needs, and innovations in rare disease therapeutics. On the second day of the conference, Migliaccio will be part of a panel on Advanced Therapy Medicinal Products (ATMPs) in the EU’s New Pharmaceutical Strategy for Europe where he will deliver a short speech on challenges and opportunities for ATMPs, followed by a panel discussion, on behalf of the European Alliance for Transformative Therapies (TRANSFORM), where EPTRI with Giovanni Migliaccio is the representative of the researchers in the “Steering Group”..

Migliaccio’s participation in this congress highlights his leadership in the field and CVBF’s commitment to collaborating across borders to advance treatments and solutions for rare disease patients. We look forward to the knowledge sharing and continued progress in rare disease strategies that this Congress will yield.

For more information about the congress, click here.